Mark Drayson

Mark Drayson
University of Birmingham · School of Immunity and Infection

BSc MBChB PhD FRCPath

About

320
Publications
29,440
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
18,391
Citations
Citations since 2016
49 Research Items
7432 Citations
201620172018201920202021202202004006008001,0001,200
201620172018201920202021202202004006008001,0001,200
201620172018201920202021202202004006008001,0001,200
201620172018201920202021202202004006008001,0001,200
Introduction
Skills and Expertise

Publications

Publications (320)
Article
Full-text available
Introduction Multiple myeloma is a plasma cell malignancy that accounts for 1%–2% of newly diagnosed cancers. At diagnosis, approximately 20% of patients can be identified, using cytogenetics, to have inferior survival (high-risk). Additionally, standard-risk patients, with detectable disease (minimal residual disease (MRD)-positive) postautologus...
Article
Full-text available
Monoclonal gammopathy (MG) is a frequently detected clonal B-cell or plasma cell disorder. Importantly, every multiple myeloma (MM) case is preceded by MG. Although clinical algorithms now allow earlier treatment of patients with biomarkers of malignancy before MM-induced tissue damage (CRAB) occurs, most patients are still diagnosed late. It is im...
Article
Full-text available
Objectives: To determine the seroprevalence of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) antibody status amongst healthcare workers (HCWs) working through the first wave of the Coronavirus (COVID-19) pandemic in 2020. To examine the association of seroprevalence and self-reported COVID-19 symptoms with occupation, sex, and ethnic...
Article
Full-text available
Introduction Multiple myeloma is a bone marrow cancer, which predominantly affects older people. The incidence is increasing in an ageing population. Over the last 10 years, patient outcomes have improved. However, this is less apparent in older, less fit patients, who are ineligible for stem cell transplant. Research is required in this patient gr...
Article
Full-text available
Myeloma patients frequently respond poorly to bacterial and viral vaccination. A few studies have reported poor humoral immune responses in myeloma patients to COVID-19 vaccination. Using a prospective study of myeloma patients in UK Rudy Study cohort, we assessed humoral and Interferon gamma release assay (IGRA) cellular immune responses to COVID-...
Preprint
Full-text available
Background: Myeloma patients frequently respond poorly to bacterial and viral vaccination. Small number of studies have reported poor humoral immune responses in myeloma patients to COVID-19 vaccination. Methods: Using a prospective study of a myeloma and smouldering myeloma patients within the UK rudystudy cohort, we assessed humoral and cellular...
Article
Background Patients with myeloma often face significant diagnostic delay, with over a quarter of patients in the UK diagnosed following emergency presentation (EP) [1]. Compared with other presentation routes, patients presenting as an emergency have more advanced disease, increased complications and poorer prognosis. Methods An economic model was...
Article
Background Minimal residual disease (MRD) status after autologous stem cell transplant (ASCT) predicts progression-free and overall survival outcomes in patients with multiple myeloma. The prognostic impact of MRD when assessed at serial time points in the context of maintenance therapy and the interaction between MRD and molecular risk are less we...
Article
Background Outcome for patients with ultra high-risk (UHiR) newly diagnosed multiple myeloma (NDMM) or plasma cell leukemia (PCL) continues to be adverse, and UHiR patients are underrepresented in clinical trials. Recently, deepened responses have been reported for anti-CD38 monoclonal antibody combination therapy in NDMM. We report here protocol d...
Article
Background Multistate models (MSMs) are an alternative to traditional survival analysis methods. MSMs describe the life history of an individual who at any time can be in any one of the states specified within the model. MSMs allow multiple events to be modelled simultaneously and patient prognosis can be predicted based on treatment and prognostic...
Preprint
Objective: Multiple myeloma (MM)-related morbidity has a profound effect on quality of life (QoL), and immune function, but few studies have prospectively examined the impact of COVID-19 pandemic and attendant vaccination on both immunity and QoL of patients with MM. We aimed to characterise these effects in a prospective cohort study. Design: We i...
Article
8001 Background: Patients with ultra high-risk (UHiR) newly diagnosed multiple myeloma (NDMM) and patients with plasma cell leukemia (PCL) continue to have dismal outcomes and are underrepresented in clinical trials. Recently, improved responses with anti-CD38 monoclonal antibody combination therapy have been reported for NDMM patients. We report h...
Article
Full-text available
Background Sex differences in the incidence and outcomes of several cancers are well established. Multiple myeloma (MM) is a malignant plasma cell dyscrasia accounting for 2% of all new cancer cases in the UK. There is a clear sex disparity in MM incidence, with 57% of cases in males and 43% in females. The mechanisms behind this are not well under...
Article
Full-text available
Autologous stem cell transplant (ASCT) remains standard of care for consolidation after induction therapy for eligible newly diagnosed myeloma patients. In recent clinical trials comparing ASCT to delayed ASCT, patients aged over 65 were excluded. In real-world practice stem cell transplants are not restricted to those aged under 65 and clinicians...
Article
Full-text available
Predicting patient outcome in multiple myeloma remains challenging despite the availability of standard prognostic biomarkers. We investigated outcome for patients relapsing early from intensive therapy on NCRI Myeloma XI. Relapse within 12 months of autologous stem cell transplant was associated with markedly worse median progression‐free survival...
Article
Monoclonal gammopathy of renal significance (MGRS) is a new concept with evolving evidence for treatment. MGRS in the transplant kidney is a rare cause of renal transplant dysfunction that can lead to graft loss. Most cases of post-transplant MGRS are due to recurrent disease. Clone-specific chemotherapy is required to target the underlying clone,...
Article
Full-text available
Disease factors such as tumor burden and molecular risk affect myeloma patient outcomes as well as patient factors that impact the capacity to deliver treatment. How the relative importance of these factors changes with patient age has not previously been investigated comprehensively. We analyzed data from 3894 patients of all ages uniformly treate...
Article
Full-text available
We previously reported the safety and efficacy of low dose BaP [Bezafibrate (Bez) and Medroxyprogesterone acetate (MPA)] in 20 acute myeloid leukaemia (AML) patients for whom chemotherapy was not an option. This study provided evidence that BaP had anti-AML activity and improved haemopoiesis; absence of haematological toxicity allowed continuous da...
Article
Full-text available
Recent studies suggest that the evolutionary history of a cancer is important in forecasting clinical outlook. To gain insight into the clonal dynamics of multiple myeloma (MM) and its possible influence on patient outcomes, we analyzed whole exome sequencing tumor data for 333 patients from Myeloma XI, a UK phase 3 trial and 434 patients from the...
Article
Pathological fractures are a common complication of plasma cell dyscrasias (PCD) and are associated with significant morbidity. Routine use of bisphosphonates over the past decade has aimed to reduce the risk of fractures in patients with multiple myeloma, but despite this, fractures continue to represent a significant burden of disease. In this st...
Article
8009 Background: Immunomodulatory (IMiD) agents are effective therapies for multiple myeloma (MM), with Lenalidomide (Len) having fewer side effects than Thalidomide (Thal), enabling long-term treatment. The optimum IMiD induction and maintenance regimen are unknown. We therefore compared triplet induction regimens of Len vs Thal and examined the r...
Conference Paper
Full-text available
Introduction Renal impairment in multiple myeloma (MM) is common and associated with worse outcomes (Augustson et al., 2005, J Clin Oncol). Diagnostic criteria for MM predominantly rely on evidence of end organ damage. The revised International Myeloma Working Group guidelines published in 2014 define renal impairment as an eGFR <40ml/min/1.73m2 or...
Conference Paper
Full-text available
Hospital episodes statistics (HES) record the ICD-10-coded diag- noses for all admissions in England and can be used to identify inpa- tient activity and define outcomes. 70,275 patients presenting with a plasma cell dyscrasia (PCD) were defined by ICD-10 codes for multiple myeloma, plasmacytoma and plasma cell leukaemia, between July 2001 and June 2...
Chapter
The immune system is mediated by many different types of haemopoietic cells, of which lymphocytes are by far the most numerous. The innate immune response provides a rapid response to infection and inflammation whereas the adaptive immune response requires the clonal expansion of antigen-specific B cells or T cells. This division is largely arbitra...
Article
Full-text available
There is a high early death rate in patients with myeloma with the single biggest cause being infection. Antibiotic prophylaxis is likely to be the most effective measure to prevent early death in this patient population. TEAMM is a randomised, double-blind, placebo-controlled multi-centre phase III clinical trial seeking to tackle early morbidity...
Article
Epigenetic dysregulation is known to be an important contributor to myeloma pathogenesis but, unlike in other B cell malignancies, the full spectrum of somatic mutations in epigenetic modifiers has not been previously reported. We sought to address this using results from whole-exome sequencing in the context of a large prospective clinical trial o...
Article
Full-text available
Bacterial infections in the elderly are common and associated with high morbidity and mortality, with pneumonia the second commonest cause of death. Reductions in antibodies against specific bacterial antigens in saliva and serum could contribute to infection risk in older adults, although they have yet to be examined in relation to age. IgG, IgA a...
Article
At the molecular level, myeloma is characterized by copy number abnormalities and recurrent translocations into the immunoglobulin heavy chain locus. Novel methods, such as massively parallel sequencing, have begun to describe the pattern of tumor-acquired mutations, but their clinical relevance has yet to be established. We performed whole-exome s...
Article
The aim of this study was to report the long-term outcomes in patients with multiple myeloma (MM) who receive dialysis treatment for acute kidney injury (AKI) due to myeloma cast nephropathy and subsequently recover renal function. Patients presenting with dialysis-dependent AKI secondary to myeloma cast nephropathy and subsequently recovering inde...
Article
Full-text available
Metabolic transformation in cancer is increasingly well understood. However, little is known about the metabolic responses of cancer cells that permit their survival in different microenvironments. We have used a nuclear magnetic resonance based approach to monitor metabolism in living primary CLL cells and to interrogate their real-time metabolic...
Article
Full-text available
The redeployed drug combination of bezafibrate and medroxyprogesterone acetate (designated BaP) has potent in vivo anticancer activity in acute myeloid leukemia (AML) and endemic-Burkitt's lymphoma (eBL) patients; however its mechanism-of-action is unclear. Given that elevated fatty acid biosynthesis is a hallmark of many cancers and that these dru...